Few companies had a year as bumpy as 23andMe had in 2024, with the company settling a lawsuit related to a data breach and announcing a round of layoffs. Amid that turmoil, many of the popular ...

Me, once valued at $6 billion, is now a penny stock. Layoffs, data breaches, and resignations led to its downfall. How did it ...

23andMe's big push into drug development, announced with great fanfare almost a decade ago, has ended with a whimper and sweeping job losses. The company that made its name by providing saliva ...

Genetic testing specialist 23andMe has launched a strategic review that could result in a sale of the company, after months of speculation about its future. The company's board has formed a ...

Morning. Today, we talk about the likely confirmation of FDA nominee Marty Makary, go in-depth on NIH nominee Jay Bhattacharya, and see how much 23andMe CEO Anne Wojcicki is willing to pay for her ...

Anna Wojcicki, the CEO of DNA testing app 23andMe that was sold for $6billion, is trying to buy the company back for just $75million. The troubled company was worth billions six years ago but now ...

"My Dad is an identical twin. So, all three of my uncle's children should be my half-siblings genetically. They did 23andMe a few years after my siblings and I did. One cousin showed up as a ...

When evaluating 23andMe's stock performance and future outlook, investors should consider short-term market trends and long-term growth potential. This analysis will dive into recent stock metrics ...

23andMe (ME) stock nosedived over 33% yesterday after the board unanimously rejected CEO Anne Wojcicki’s takeover offer. The company has set up a Special Committee of the Board of Directors to ...

23andMe ME1.34%increase; green up pointing triangle rejected its chief executive’s proposal to buy back the company at 41 cents a share as the struggling company explores strategic alternatives ...